002007 华兰生物
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入762,111-12.16%4,595,0184,379,1975,341,8734,516,979
减:营业总成本545,395-1.48%3,373,6623,124,9673,424,9913,113,193
    其中:营业成本379,6260.08%1,951,5381,688,2411,624,4781,532,865
               财务费用(972)-361.18%458(6,843)(1,672)9,679
               资产减值损失200-80.88%(58,208)(74,225)(90,879)(157,297)
公允价值变动收益4,067-25.41%15,17232,94060,54436,107
投资收益33,140-13.80%62,498137,518149,046107,946
    其中:对联营企业和合营企业的投资收益7,257--(85,089)(26,440)(25,645)(26,407)
营业利润298,558-24.88%1,228,5421,379,5822,098,3901,424,463
利润总额289,500-24.72%1,173,3481,338,6132,077,6431,428,368
减:所得税费用46,906-22.78%173,356183,143315,958180,765
净利润242,594-25.09%999,9931,155,4701,761,6851,247,603
减:非控股权益12,24514.49%59,59267,619280,106171,338
股东净利润230,349-26.44%940,4011,087,8511,481,5791,076,265

市场价值指针
每股收益 (元) *0.126-26.53%0.5150.5960.8120.590
每股派息 (元) *----1.0000.2000.3000.300
每股净资产 (元) *6.413-3.64%6.2936.4856.2115.700
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容